Back HIV/AIDS

HIV / AIDS

Kaletra Label Updated to Add Drug Interactions, Including Boceprevir and Telaprevir

Product label information for the HIV protease inhibitor lopinavir/ritonavir (Kaletra) was revised to include information about several additional medications with the potential for drug-drug interactions, the U.S. Food and Drug Administration (FDA) announced last week.

alt

Very Early HIV Treatment May Delay Disease Progression, Raise CD4 Count

Starting antiretroviral therapy (ART) within the first 6 months after infection may slow immune system decline and raise CD4 T-cell counts, but the benefits may not last after treatment is stopped, according to a pair of studies published in January 17, 2013, New England Journal of Medicine.

alt

Generic HIV Drugs Could Save Millions, But May Reduce Effectiveness

Using separate generic pills instead of a brand-name 3-in-1 coformulation could save more than $900 million during the first year, but such a switch could also lead to reduced adherence to antiretroviral therapy (ART) and poorer treatment outcomes, according to a mathematical model described in the January 15, 2013, Annals of Internal Medicine.

alt

HIV Treatment Interruption Associated with Reduced Bone Loss in SMART Trial

People who stopped antiretroviral therapy (ART) in the SMART trial had less bone loss and lower levels of bone metabolism biomarkers than people who remained on continuous treatment, according to a report in the January 8, 2013, advance edition of Journal of Bone Mineral Research.

alt

Lancet: Dolutegravir Works as Well as Raltegravir for First-time HIV Treatment

The next-generation HIV integrase inhibitor dolutegravir worked as well as raltegravir (Isentress), an approved drug in this class, for treatment-naive people in the Phase 3 SPRING-2 trial, according to a report published in the January 8, 2013, advance edition of The Lancet.
alt

Dendritic Cell Therapeutic Vaccine Helps Immune Cells Control HIV Replication

A therapeutic vaccine made from dendritic cells primed with heat-inactivated HIV stimulated immune cells to mount a response against the virus without it infecting and killing them, according to a study described in the January 2, 2013, issue of Science Translational Medicine.

alt

New Findings Help Explain Inconsistent Protection in Preventive HIV Vaccine Trial

Researchers have discovered variations in the structure of specific antibodies targeting the HIV envelope that may help explain why the ALVAC/AIDSVAX combination vaccine tested in a large trial in Thailand appeared to protect some participants but not others.

alt